Rigora · CROs · Partnership
For mid-size and specialty CROs
Win the bid on AI-native capability.
Rigora is an AI-native clinical monitoring layer you can bundle into your service offering, for drug trials and device studies alike. Compete with the largest CROs on technical capability without the engineering investment, and run more studies with the CRA team you have.
The partnership
How this partnership works.
Improve bid win rate, margin, and brand control.
Bids
Win bids on capability, not price.
AI-native monitoring is showing up in large-CRO proposals. Bundling Rigora lets you answer with a working capability: drafted reports, provenance, an audit trail. No multi-year internal build.
Margin
Convert templated hours into margin.
Most monitoring labor is templated: source data verification, visit-report drafting, query writing. Rigora targets that layer. Efficiency is measured per pilot and published, not promised up front. Reinvest the hours in higher-value CRA work, or take them as margin.
Brand
White-label deployment.
Rigora runs under your brand, so sponsors see your monitoring capability, not ours. Multi-sponsor isolation is built in, and your portfolio stays yours.
Partner fit
Who we partner with
Mid-size and specialty CROs with a live portfolio of monitored studies. Drug trials or device studies alike (pivotal and post-market follow-up under ISO 14155).
Monitoring-heavy programs: oncology, neurology, immunology, rare disease, or Class II/III device studies.
Appetite for AI-native capability as a competitive lever.
Willingness to co-invest in a 90-day pilot on one live study.
Non-fit
Who we do not partner with
CROs whose primary differentiator is low-cost labor (our economics compress yours, not expand them).
CROs unwilling to share proposal-stage pipeline with Rigora (we can't help you win bids we don't know you're submitting).
Partnerships